case_images: PMC9389067_01
case_images: PET/CT scan in September 2020 showing disease progression after radiotherapy. Bone metastases (A), lymph nodes in the mediastinum and diaphragm (B, E), lung metastases (C), and pleural metastases (D) show progression compared with scans in April 2020.
case_images: fonc-12-923683-g001.jpg
case_images: PMC9389067_01_fonc-12-923683-g001.jpg
case_images: f1
case_images: In September 2020, a PET/CT scan showed that the lung, pleura, and bone metastases were all progressing (Figure 1).
case_images: PET/CT scans showing disease response to lenvatinib treatment. The lesions in the right lung and right pleura were substantially smaller, and the metabolism of the lung, pleural, and bone metastases was decreased in March 2021 (G-L) compared with that in September 2020 (A-F).
case_images: fonc-12-923683-g002.jpg
case_images: PMC9389067_01_fonc-12-923683-g002.jpg
case_images: f2
case_images: Summary of the treatment timeline of this case.
case_images: fonc-12-923683-g003.jpg
case_images: PMC9389067_01_fonc-12-923683-g003.jpg
case_images: f3
case_images: The timeline for treatments and efficacy evaluations in this case is summarized in Figure 3.
case_images: The histology and IHC staining of pleural nodule biopsy. The pathology showed that the immunohistochemical phenotype of tumor tissue supported the characteristics of thymic epithelial differentiation. Immunohistochemistry: CD5 (+), CK5 (+), CD117 (+), PCK (+), and TTF-1 (-).
case_images: fonc-12-923683-g004.jpg
case_images: PMC9389067_01_fonc-12-923683-g004.jpg
case_images: f4
case_images: Immunohistochemistry staining was positive for CD5, CK5, CD117, and PCK and negative for TTF-1 (Figure 4).